Tag Archives: patent

New Patented Drugs Save Us All Money and Help Those in Dire Need

Money and Savings

New patented drugs actually save the United States and its citizens lots of money. In fact, new drugs save 7 times more in non-drug spending than they cost.  Those savings come as new drugs result in reduced hospital and nursing home admissions which far exceed the cost of using newer drugs.  New patented prescription drugs can also reduce the need for expensive surgeries and hospital stays. This data clearly articulates that the cost of treating Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , ,

India Compulsory License: A Times of India Article Says It’s Not Helping the Poor

india-btn

India recently issued a compulsory license on Bayer’s liver and kidney cancer drug (Sorafenib) with the stated goal of providing access to India’s poor. However, the Times of India recently ran the article Cheap generics drugs no panacea for India’s poorest, quickly dispelling this myth: “The compulsory license system might not really work because poor people cannot even afford the discounted price,” said G. Balachandhran, former head of the National Pharmaceutical Pricing Authority (NPPA), India’s drug Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , ,

Mayo v. Prometheus: BIO Statement on Supreme Court Decision

U.S. Supreme Court

By Hans Sauer, Deputy General Counsel for Intellectual Property, Biotechnology Industry Organization We are surprised and disappointed in the Court’s decision, which disregarded the considered judgment of the Executive Branch experts and numerous amici such as BIO, who warned about the unintended consequences of attempting to use patent eligibility as a basis to strike down these patents for biomarker-based diagnostic methods. While we are still analyzing the opinion, we are concerned that it introduces new and Read More >

Patently BIOtech  |  1 Comment  |  Email This Post
Tags: , , , , , , ,

Patent “Ever-Greening”: Novartis Confronts Patent Myth in India

Pine

India’s ‘increased efficacy’ patentability requirement for medicines prevents an improved form of a known drug from receiving a patent unless the new form is significantly more effective than the previously-known form. This provision aims to accomplish one task: stop patent “ever-greening.”  This issue has risen to prominence lately as the New York Times reports on the Novartis suit challenging patent ever-greening requirements in India’s Supreme Court. So what is patent ever-greening?  Opponents claim that corporations Read More >

Patently BIOtech  |  2 Comments  |  Email This Post
Tags: , , , , , , , , , ,

Patents for Humanity

Kappos-200

By David Kappos, Director of the United States Patent and Trademark Office (USPTO) Originally Published on USPTO Director’s Forum Sweeping revolutions in technology continue to fundamentally redefine the way we connect with one another and interact with the world. Today, an entrepreneur can do business with a remote village across an ocean just as quickly as a student in Boston can video-conference with a professor in Beijing. Political rallies can be organized by the click of Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,